(SANA) Sana Biotechnology - Overview
Stock: Islet Cell Therapy, CAR-T Cell Therapy, Fusosome Therapy, Hypoimmune Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 112% |
| Relative Tail Risk | -14.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.68 |
| Alpha | -8.30 |
| Character TTM | |
|---|---|
| Beta | 1.956 |
| Beta Downside | 1.137 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.11% |
| CAGR/Max DD | -0.03 |
Description: SANA Sana Biotechnology December 26, 2025
Sana Biotechnology (NASDAQ:SANA) is a Seattle-based biotech that builds engineered-cell medicines for unmet needs in type 1 diabetes, B-cell-mediated autoimmunity, and oncology. Its pipeline includes the allogeneic HIP-modified islet product UP421 (Phase 1 for type 1 diabetes), the stem-cell-derived islet candidate SC451 (preclinical), the CD19-directed CAR-T SC291 (Phase 1 for systemic lupus erythematosus and ANCA-associated vasculitis, plus preclinical programs), the CD22-directed hypoimmune CAR-T SC262 (Phase 1 for non-Hodgkin’s lymphoma), and the CD8-targeted fusosome SG299 (preclinical for hematologic cancers and autoimmune disease). The company leverages Beam Therapeutics’ CRISPR Cas12b platform and Harvard-licensed hypoimmune cell technology under exclusive licenses.
As of the latest 10-Q (Q2 2024), Sana reported a cash runway of roughly $350 million with a quarterly burn of $120 million, reflecting heavy R&D investment typical for early-stage cell-therapy firms. The broader cell-therapy market is projected to grow at a CAGR of 15-20 % through 2030, driven by expanding FDA approvals of allogeneic CAR-T products and increasing payer acceptance of curative-intent biologics. Sana’s focus on “off-the-shelf” allogeneic platforms positions it to capture scalability advantages relative to autologous competitors, a key sector driver that could accelerate revenue timelines if clinical milestones are met.
For a deeper, data-driven view of Sana’s valuation metrics and scenario analysis, you may find the ValueRay platform worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -234.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA 12.68 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.36 > 3% & CFO -158.3m > Net Income -234.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (260.5m) vs 12m ago 10.65% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.07% > 50% (prev 0.0%; Δ 3.07% > 0%) |
| Interest Coverage Ratio: -4.80 > 6 (EBITDA TTM -178.6m / Interest Expense TTM 40.4m) |
Altman Z'' -15.00
| A: 0.29 (Total Current Assets 161.8m - Total Current Liabilities 35.5m) / Total Assets 435.4m |
| B: -4.11 (Retained Earnings -1.79b / Total Assets 435.4m) |
| C: -0.39 (EBIT TTM -194.0m / Avg Total Assets 497.4m) |
| D: -7.46 (Book Value of Equity -1.79b / Total Liabilities 240.1m) |
| Altman-Z'' Score: -21.95 = D |
What is the price of SANA shares?
Over the past week, the price has changed by -11.29%, over one month by -9.86%, over three months by -2.96% and over the past year by +20.55%.
Is SANA a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SANA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.7 | 121.6% |
| Analysts Target Price | 8.7 | 121.6% |
| ValueRay Target Price | 4 | 1.5% |
SANA Fundamental Data Overview February 03, 2026
Revenue TTM = 15.3m USD
EBIT TTM = -194.0m USD
EBITDA TTM = -178.6m USD
Long Term Debt = 82.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.8m USD (from shortTermDebt, last quarter)
Debt = 89.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.12b USD (1.18b + Debt 89.7m - CCE 153.1m)
Interest Coverage Ratio = -4.80 (Ebit TTM -194.0m / Interest Expense TTM 40.4m)
EV/FCF = -7.03x (Enterprise Value 1.12b / FCF TTM -158.8m)
FCF Yield = -14.23% (FCF TTM -158.8m / Enterprise Value 1.12b)
FCF Margin = -1039 % (FCF TTM -158.8m / Revenue TTM 15.3m)
Net Margin = -1534 % (Net Income TTM -234.4m / Revenue TTM 15.3m)
Gross Margin = 7.43% ((Revenue TTM 15.3m - Cost of Revenue TTM 14.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.56 (Enterprise Value 1.12b / Total Assets 435.4m)
Interest Expense / Debt = 2.15% (Interest Expense 1.93m / Debt 89.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -153.3m (EBIT -194.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.55 (Total Current Assets 161.8m / Total Current Liabilities 35.5m)
Debt / Equity = 0.46 (Debt 89.7m / totalStockholderEquity, last quarter 195.3m)
Debt / EBITDA = 0.08 (negative EBITDA) (Net Debt -13.6m / EBITDA -178.6m)
Debt / FCF = 0.09 (negative FCF - burning cash) (Net Debt -13.6m / FCF TTM -158.8m)
Total Stockholder Equity = 194.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.13% (Net Income -234.4m / Total Assets 435.4m)
RoE = -120.6% (Net Income TTM -234.4m / Total Stockholder Equity 194.4m)
RoCE = -70.14% (EBIT -194.0m / Capital Employed (Equity 194.4m + L.T.Debt 82.2m))
RoIC = -78.86% (negative operating profit) (NOPAT -153.3m / Invested Capital 194.4m)
WACC = 12.31% (E(1.18b)/V(1.27b) * Re(13.12%) + D(89.7m)/V(1.27b) * Rd(2.15%) * (1-Tc(0.21)))
Discount Rate = 13.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.90%
Fair Price DCF = unknown (Cash Flow -158.8m)
EPS Correlation: 60.62 | EPS CAGR: 45.04% | SUE: 2.07 | # QB: 1
Revenue Correlation: 25.21 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.57 | Chg30d=+0.007 | Revisions Net=+0 | Growth EPS=+22.1% | Growth Revenue=+0.0%